Literature DB >> 33450394

Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.

Sandeep Kumar1, Sunil Kumar Singh2, Basabi Rana3, Ajay Rana3.   

Abstract

Host immunity has an essential role in the clinical management of cancers. Therefore, it is advantageous to choose therapies that can promote tumor cell death and concurrently boost host immunity. The dynamic tumor microenvironment (TME) determines whether an antineoplastic drug will elicit favorable or disparaging immune responses from tumor-infiltrating lymphocytes (TILs). CD8+ T cells are one of the primary tumor-infiltrating immune cells that deliver antitumor responses. Here, we review the influence of various factors in the TME on CD8+ T cell exhaustion and survival, and possible strategies for restoring CD8+ T cell effector function through immunotherapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33450394      PMCID： PMC8131230          DOI： 10.1016/j.drudis.2021.01.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   8.369


  207 in total

Review 1.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

3.  2B4 but not PD-1 blockade improves mortality in septic animals with preexisting malignancy.

Authors:  Ching-Wen Chen; Ming Xue; Wenxiao Zhang; Jianfeng Xie; Craig M Coopersmith; Mandy L Ford
Journal:  JCI Insight       Date:  2019-11-14

4.  Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.

Authors:  Jordana G Coelho-Dos-Reis; Jing Huang; Tiffany Tsao; Felipe V Pereira; Ryota Funakoshi; Hiroko Nakajima; Haruo Sugiyama; Moriya Tsuji
Journal:  Clin Immunol       Date:  2016-04-27       Impact factor: 3.969

5.  A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.

Authors:  Xilai Ding; Guanglin Bian; Nicholas D Leigh; Jingxin Qiu; Philip L McCarthy; Hong Liu; Semra Aygun-Sunar; Lyudmila G Burdelya; Andrei V Gudkov; Xuefang Cao
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

6.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.

Authors:  Yannick Simoni; Etienne Becht; Michael Fehlings; Chiew Yee Loh; Si-Lin Koo; Karen Wei Weng Teng; Joe Poh Sheng Yeong; Rahul Nahar; Tong Zhang; Hassen Kared; Kaibo Duan; Nicholas Ang; Michael Poidinger; Yin Yeng Lee; Anis Larbi; Alexis J Khng; Emile Tan; Cherylin Fu; Ronnie Mathew; Melissa Teo; Wan Teck Lim; Chee Keong Toh; Boon-Hean Ong; Tina Koh; Axel M Hillmer; Angela Takano; Tony Kiat Hon Lim; Eng Huat Tan; Weiwei Zhai; Daniel S W Tan; Iain Beehuat Tan; Evan W Newell
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

7.  Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.

Authors:  Hyunjoon Kim; Lin Niu; Peter Larson; Tamara A Kucaba; Katherine A Murphy; Britnie R James; David M Ferguson; Thomas S Griffith; Jayanth Panyam
Journal:  Biomaterials       Date:  2018-02-17       Impact factor: 12.479

8.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Authors:  Deborah H Charych; Ute Hoch; John L Langowski; Steve R Lee; Murali K Addepalli; Peter B Kirk; Dawei Sheng; Xiaofeng Liu; Paul W Sims; Laurie A VanderVeen; Cherie F Ali; Thomas K Chang; Marina Konakova; Rhoneil L Pena; Rupesh S Kanhere; Yolanda M Kirksey; Chunmei Ji; Yujun Wang; Jicai Huang; Theresa D Sweeney; Seema S Kantak; Stephen K Doberstein
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

9.  IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.

Authors:  Alistair Noble; Hema Mehta; Andrew Lovell; Eleftheria Papaioannou; Lynette Fairbanks
Journal:  Eur J Immunol       Date:  2016-04-08       Impact factor: 5.532

10.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Alexander Drilon; Jedd D Wolchok; Richard D Carvajal; M Brent McHenry; Fareeda Hosein; Christopher T Harbison; Joseph F Grosso; Mario Sznol
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777
View more
  4 in total

Review 1.  Resilient T-cell responses in patients with advanced cancers.

Authors:  Joanina K Gicobi; Emilia R Dellacecca; Haidong Dong
Journal:  Int J Hematol       Date:  2022-07-21       Impact factor: 2.319

2.  Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.

Authors:  Karina Cereceda; Nicolas Bravo; Roddy Jorquera; Roxana González-Stegmaier; Franz Villarroel-Espíndola
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

Review 3.  Dysregulation of immune checkpoint proteins in hepatocellular carcinoma: Impact on metabolic reprogramming.

Authors:  Kanchan Vishnoi; Sandeep Kumar; Rong Ke; Ajay Rana; Basabi Rana
Journal:  Curr Opin Pharmacol       Date:  2022-05-05       Impact factor: 4.768

4.  The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.

Authors:  Virginia Liberini; Riccardo Laudicella; Martina Capozza; Martin W Huellner; Irene A Burger; Sergio Baldari; Enzo Terreno; Désirée Deandreis
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.